Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of a combination therapy consisting of ...

Princeton: Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...

At the forefront is its blockbuster immuno-oncology drug, Opdivo, complemented by heavy hitters like Revlimid, Pomalyst, ...

IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of ...

Perioperative chemoimmunotherapy for resectable non-small cell lung cancer (NSCLC) shows promising long-term benefits with ...

Bristol Myers (BMY) announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has recommended approval of Opdivo plus Yervoy for the ...

Patients with MSI-high/dMMR advanced colorectal cancers had a 79 percent lower risk of disease progression or death on Opdivo-Yervoy compared to chemo.

JMP Securities initiates coverage on Summit Therapeutics, citing promising data for ivonescimab in NSCLC and setting a $32 ...

Patients with metastatic non-small cell lung cancer, even those with brain metastases, experienced improved longer-term ...

More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...

Dr Meredith Edwards, Country Medical Director, Bristol Myers Squibb New Zealand, said, “The funding of OPDIVO as a treatment option for previously treated advanced clear cell renal cell carcinoma ...